Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia
International Journal of Molecular Sciences · 20.01.2025 · 26 (2) · 835
DOI: 10.3390/ijms26020835 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.01.2025. Verfasst von Kazufumi Nakamura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Hypoxia, Lung Diseases. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research, Ryobi Teien Memory Foundation, JSPS KAKENHI.
Abstract (Originalsprache)
Pulmonary hypertension associated with lung diseases and/or hypoxia is classified as group 3 in the clinical classification of pulmonary hypertension. The efficacy of existing selective pulmonary vasodilators for group 3 pulmonary hypertension is still unknown, and it is currently associated with a poor prognosis. The mechanisms by which pulmonary hypertension occurs include hypoxic pulmonary vasoconstriction, pulmonary vascular remodeling, a decrease in pulmonary vascular beds, endothelial dysfunction, endothelial-to-mesenchymal transition, mitochondrial dysfunction, oxidative stress, hypoxia-inducible factors (HIFs), inflammation, microRNA, and genetic predisposition. Among these, hypoxic pulmonary vasoconstriction and subsequent pulmonary vascular remodeling are characteristic factors involving the pulmonary vasculature and are the focus of this review. Several factors have been reported to mediate vascular remodeling induced by hypoxic pulmonary vasoconstriction, such as HIF-1α and mechanosensors, including TRP channels. New therapies that target novel molecules, such as mechanoreceptors, to inhibit vascular remodeling are awaited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
- Center for Advanced Heart Failure, Okayama University Hospital, Okayama 700-8558, Japan.
- Department of Pharmacy, Kinjo Gakuin University, Nagoya 463-8521, Japan.
- Graduate School of Pharmaceutical Sciences, Kinjo Gakuin University, Nagoya 463-8521, Japan.
ORCID-Profile: Kazufumi Nakamura, Satoshi Akagi
Förderung
- Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research
- Ryobi Teien Memory Foundation
- JSPS KAKENHI
Zitieren
APA
Nakamura, K., Akagi, S., Ejiri, K., Taya, S., Saito, Y., Kuroda, K., Takaya, Y., Toh, N., Nakayama, R., Katanosaka, Y., & Yuasa, S. (2025). Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia. International Journal of Molecular Sciences, 26(2), 835. https://doi.org/10.3390/ijms26020835
Vancouver
Nakamura K, Akagi S, Ejiri K, Taya S, Saito Y, Kuroda K, et al. Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia. International Journal of Molecular Sciences. 2025;26(2):835. doi:10.3390/ijms26020835
BibTeX
@article{Nakamura2025,
author = {Nakamura, Kazufumi and Akagi, Satoshi and Ejiri, Kentaro and Taya, Satoshi and Saito, Yukihiro and Kuroda, Kazuhiro and Takaya, Yoichi and Toh, Norihisa and Nakayama, Rie and Katanosaka, Yuki and Yuasa, Shinsuke},
title = {Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {2},
pages = {835},
doi = {10.3390/ijms26020835}
}
EUVIMED